Uncomplicated Peptic Ulcer without MCC DRG Reimbursement

DRG 384 pertains to inpatient stays for uncomplicated peptic ulcer disease without Major Complication or Comorbidity, encompassing straightforward medical or endoscopic management. Proper assignment matters for inpatient reimbursement because it reflects lower expected resource use and influences Medicare payment classification.

DRG 384 Overview

DRG 384 covers hospital admissions for uncomplicated peptic ulcer disease without Major Complication or Comorbidity, typically managed with medical therapy or limited endoscopic intervention. This Diagnosis-Related Group groups patients with relatively low resource use compared with ulcer cases that have complications, which affects payment assignment and hospital case-mix. For Medicare payment, accurate coding of ulcer diagnosis and absence of Major Complication or Comorbidity is essential to assign this Diagnosis-Related Group and determine inpatient reimbursement. Understanding this clinical scope helps clarify expected resource intensity and billing classification.

Acute management randomized trials comparing strategies for initial hemostasis in hospitalized patients with bleeding peptic ulcers: these studies enroll adults admitted with active upper GI bleeding or recent endoscopic evidence of ulcer bleeding and randomize to different endoscopic techniques, adjunctive pharmacologic protocols, or timing of second-look endoscopy. The objective is to determine which immediate interventions reduce rebleeding, transfusion needs, length of stay, and inpatient resource utilization. Results inform clinicians on best-practice acute care pathways and help payers anticipate procedure use and short-term cost drivers for this DRG.
Comparative effectiveness studies of maintenance medical regimens to prevent recurrent ulcer complications in patients without major comorbidities: prospective cohort or pragmatic randomized trials evaluate different acid suppression strategies, Helicobacter pylori testing-and-eradication pathways, and NSAID-sparing protocols among patients hospitalized for uncomplicated peptic ulcer disease. These studies focus on mid-term outcomes such as recurrence rates, readmissions, medication adherence, and adverse effects, addressing the transition from inpatient stabilization to outpatient prevention. Findings are relevant for discharge planning, formulary decisions, and reducing readmission-associated costs for the uncomplicated peptic ulcer population.
Post-discharge outcomes and health services research examining factors associated with readmission, functional recovery, and outpatient follow-up adherence in patients treated for uncomplicated peptic ulcers: observational registry studies or claims-based analyses identify predictors (for example, socioeconomic status, follow-up access, H. pylori eradication status) of 30- and 90-day readmissions and downstream complications. The aim is to quantify real-world utilization patterns, long-term morbidity, and cost implications of different discharge care bundles or care coordination interventions. This research guides quality improvement initiatives, care transition programs, and payer strategies to reduce avoidable post-discharge utilization in this DRG.

Acute management randomized trials comparing strategies for initial hemostasis in hospitalized patients with bleeding peptic ulcers: these studies enroll adults admitted with active upper GI bleeding or recent endoscopic evidence of ulcer bleeding and randomize to different endoscopic techniques, adjunctive pharmacologic protocols, or timing of second-look endoscopy. The objective is to determine which immediate interventions reduce rebleeding, transfusion needs, length of stay, and inpatient resource utilization. Results inform clinicians on best-practice acute care pathways and help payers anticipate procedure use and short-term cost drivers for this DRG.
Comparative effectiveness studies of maintenance medical regimens to prevent recurrent ulcer complications in patients without major comorbidities: prospective cohort or pragmatic randomized trials evaluate different acid suppression strategies, Helicobacter pylori testing-and-eradication pathways, and NSAID-sparing protocols among patients hospitalized for uncomplicated peptic ulcer disease. These studies focus on mid-term outcomes such as recurrence rates, readmissions, medication adherence, and adverse effects, addressing the transition from inpatient stabilization to outpatient prevention. Findings are relevant for discharge planning, formulary decisions, and reducing readmission-associated costs for the uncomplicated peptic ulcer population.
Post-discharge outcomes and health services research examining factors associated with readmission, functional recovery, and outpatient follow-up adherence in patients treated for uncomplicated peptic ulcers: observational registry studies or claims-based analyses identify predictors (for example, socioeconomic status, follow-up access, H. pylori eradication status) of 30- and 90-day readmissions and downstream complications. The aim is to quantify real-world utilization patterns, long-term morbidity, and cost implications of different discharge care bundles or care coordination interventions. This research guides quality improvement initiatives, care transition programs, and payer strategies to reduce avoidable post-discharge utilization in this DRG.

OpenPayer

Summary & Overview

Uncomplicated Peptic Ulcer without MCC: Inpatient Reimbursement Overview

DRG 384 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes